Hypouricemic action of scopoletin arising from xanthine oxidase inhibition and uricosuric activity.
Scopoletin exhibited an immediate and dose-dependent hypouricemic effect after intraperitoneal administration (50, 100, 200 mg/kg) in hyperuricemic mice induced by potassium oxonate; however, it did not affect the serum uric acid level in normal mice at the tested doses. For exploring the involved mechanisms of action of scopoletin, potential inhibitory effects on xanthine oxidase and possible uricosuric effects were investigated. Scopoletin (50, 100, 200 mg/kg) significantly inhibited the activity of xanthine oxidase in liver homogenates of hyperuricemic mice although it only showed a relatively weak, albeit competitive-type, inhibition of xanthine oxidase in a commercial assay. Furthermore, a potent uricosuric effect of scopoletin (100, 200 mg/kg) was ascertained. These results demonstrated for the first time that scopoletin exhibits, hypouricemic activities through decreasing uric acid production and as well as a uricosuric mechanism.
Ding
Zuoqi
Z
Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, Nanjing, People's Republic of China.
Dai
Yue
Y
Wang
Zhengtao
Z
D000818:Animals; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018547:Plant Stems; D010946:Plants, Medicinal; D012603:Scopoletin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D014528:Uricosuric Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D010936:Plant Extracts; D014528:Uricosuric Agents; D014969:Xanthine Oxidase; D012603:Scopoletin